TRIANNI Issued Patent in Australia

Trianni, Inc. is delighted to announce that the Trianni Mouse Platform was granted an Australian Patent. The Trianni Mouse Platform provides the complete human antibody repertoire for the facile isolation of monoclonal antibodies.

Trianni, Inc. is delighted to announce that the Trianni Mouse Platform was granted an Australian Patent. The Trianni Mouse Platform provides the complete human antibody repertoire for the facile isolation of monoclonal antibodies. 

“The addition of the Australian patent to our portfolio strengthens Trianni’s position in monoclonal antibody discovery platform,” commented Dr. Matthias Wabl, Ph.D., Chairman and CEO of Trianni. “It recognizes the novelty of the approach that Trianni used to generate the platform. Rather than cloning DNA fragments from the human genome, Trianni used chemically synthesized large DNA segments with sequences that do not exist in nature. Designed in silico, these segments are modified versions of the mouse immunoglobulin loci, with human exons embedded in mouse control regions and intergenic DNA.”


Categories: Pharmaceuticals and Biotech, Patents and Copyright, Medical Research

Tags: antibodies, antibody, biologics, humanized, in-licensing, mice, monoclonal, out-licensing, platform


About TRIANNI, inc.

View Website

TRIANNI offers a fully humanized monoclonal antibody platform. TRIANNI's technology is distinguished by key advantages of ease of use, antibody diversity, and in vivo selection.